Mutant Type Glutathione S-transferase Theta 1 Gene Homologue to mTOR in Myelodysplastic Syndrome: Possible Clinical Application of Rapamycin

References

• Morel, P., Hebbar, M., Lai, J.L., et al. (1993) "Cytogenetic analysis has strong independent prognosis value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases", Leukemia 7, 1315–1323.
   PubMed Web of Science ®Google Scholar
• Mulfi, G.I. (1992) "Chromosomal deletions in the myelodysplastic syndromes", Leuk. Res. 16, 35–41.
   PubMed Web of Science ®Google Scholar
• Nowell, P.C. (1992) "Chromosomal abnormalities in myelo-dysplastic syndromes", Semin. Oncol. 19, 25–33.
   PubMed Web of Science ®Google Scholar
• Toyama, K., Ohyashiki, K., Yoshida, Y, et al. (1993) "Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan", Leukemia 7, 499–508.
   PubMed Web of Science ®Google Scholar
• West, R.R., Stafford, D.A., Farrow, A. and Jacobs, A. (1995) "Occupational and environmental exposures and myelodysplasia: a case-control study", Leuk. Res. 19, 127–139.
   PubMed Web of Science ®Google Scholar
• Aul, C., Bowen, D.T. and Yoshida, Y. (1998) "Pathogenesis, etiology and epidermiology of myelodysplastic syndromes", Hematologica 83, 71–86.
   PubMed Web of Science ®Google Scholar
• Ketterer, B. (1988) "The protective role of glutathione transferase in mutagenesis and carcinogenesis", Mutat. Res. 202, 343–361.
   PubMed Web of Science ®Google Scholar
• Mooney, L.A., Bell, D.A., Santella, R.M., et al. (1997) "Contribution of genetic and nutritional factors to DNA damage in heavy smokers", Carcinogenesis 18, 503–509.
   PubMed Web of Science ®Google Scholar
• Mannervik, B., Awasthi, Y.C., Board, P.G., et al. (1992) "Nomenclature for human glutathione transferase", Biochem. J. 282, 305–306.
   PubMed Web of Science ®Google Scholar
• Siedegard, J., Pero, R.W., Markowitz, maw, Roush, G., Miller, D.G. and Beattie, E.J. (1990) "Isozymes of glutathione 5-transferase (Clasee Mu) as a marker for the susceptibility to lung cancer. A follow up study", Carcinogenesis 11, 33–36.
   PubMed Web of Science ®Google Scholar
• Daly, AK., Thomas, D.J., Cooper, J., Pearson, W.R., Neal, D.E. and Idle, T.R. (1993) "Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer", BMJ 307, 481–482.
   PubMed Web of Science ®Google Scholar
• Pemble, S., Schroader, KR., Spencer, S.R., et al. (1994) "Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism", Biochem. J. 300, 271–276.
   PubMed Web of Science ®Google Scholar
• Chen, H., Standler, D.P., Taylor, L.A., et al. (1996) "Increased risk for myelodysplastic syndrome in individuals with glutathione transferase theta 1 (GSTT1) gene defect", Lancet 347, 295–297.
   PubMed Web of Science ®Google Scholar
• Basu, T., Gale, RE., Langabeer, S. and Linch, D.C. (1997) "Glutathione 5-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia", Lancet 349, 1450.
   PubMed Web of Science ®Google Scholar
• Atoyebi, W., Kusec, R., Fidler, C., Peto, E.A., Boultwood, J. and Wainscoat, J.S. (1997) "Glutathione S-transferase gene deletion in myelodysplasia", Lancet 349, 1450.
   PubMed Web of Science ®Google Scholar
• Pseudohomme, C., Nisse, C., Hebbar, M., et al. (1997) "Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens", Leukemia 11, 1580–1582.
   PubMed Web of Science ®Google Scholar
• Okada, M., Okamoto, T., Wada, H., Takemoto, Y. and Kakishita, E. (1997) "Glutathione S transferase theta 1 gene (GSTTI) defect in Japanese patients with myelodysplastic syndromes", Int. J. Hematol. 66, 393–394.
   PubMed Web of Science ®Google Scholar
• Maeda, Y, Sumimoto, Y, Nawata, H., Matsuda, M. and Kanamaru, A. (1998) "Deleted mutation of GSTT-1 gene in patients with MDS", Leukemia 12, 2039.
   PubMed Web of Science ®Google Scholar
• Sabers, C.J., Martin, maw, Brunn, G.J., et al. (1995) "Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells", J. Biol. Chem. 270, 815–822.
   PubMed Web of Science ®Google Scholar
• Brown, EL, Albers, MW., Shin, TB., et al. (1994) "A mammalian protein targeted by G1 -arresting rapamycin-receptor complex", Nature 369, 756–758.
   PubMed Web of Science ®Google Scholar
• Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P. and Snyder, S.H. (1994) "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", Cell 78, 35–43.
   PubMed Web of Science ®Google Scholar
• Chiu, ML, Katz, H., Berlin, V, et al. (1994) "RAPTI, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex", Proc. Nall Acad. Sci. USA 91, 12574–12578.
   PubMed Web of Science ®Google Scholar
• Dumont, F.J. and Su, Q. (1996) "Mechanism of action of the immunosuppressant rapamycin", Life Sci. 58, 373–395.
   PubMed Web of Science ®Google Scholar
• Sehgal, S.N., Molnar-Kimber, K., Ocain, T.D. and Weichman, B.M. (1994) "Rapamycin: a novel irmnunosuppressive macrolide", Med. Res. Rev. 14, 1–22.
   PubMed Web of Science ®Google Scholar
• Dilling, MB., Dias, P., Shapiro, D.N., German, G.S., Johnson, R.K. and Houghton, P.J. (1994) "Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibitor of signaling via the type I insulin-like growth factors receptor", Cancer Res. 54, 903–907.
   PubMed Web of Science ®Google Scholar
• Hosoi, H., Dilling, MB., Liu, N., et al. (1998) "Studies on the mechanism of resistance to rapamycin in human cancer cells", Mol. Phannacol. 54, 815–824.
   PubMed Web of Science ®Google Scholar
• Calestretti, A., Racati, F., Ceriani, M.C., Asnaghi, L., Canti, G. and Nicolin, A. (2001) "Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect", Eur. J. Cancer 37, 2121–2128.
   PubMed Web of Science ®Google Scholar
• Hidalgo, M. and Rowinsky, E.K. (2000) "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene 19, 6680–6686.
   PubMed Web of Science ®Google Scholar
• Dudkin, L., Dilling, MB., Cheshire, P.J., et al. (2001) "Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor inhibition", Clin. Cancer Res. 7, 1758–1764.
   PubMed Web of Science ®Google Scholar
• Yu, K., Toral-Barza, L., Discafani, C., et al. (2001) "mTOR, a novel target in breast cancer: the effect of CCI-779, a TOR inhibitor, in preclinical model of breast cancer", Endocr-Relat. Cancer 8, 249–258.
   PubMed Web of Science ®Google Scholar
• Geoerger, B., Kerr, K., Tan, C.B., et al. (2001) "Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroecto-dermal tumor/medulloblastoma model as single agent in combi-nation chemotherapy", Cancer Res. 61, 1527–1532.
   PubMed Web of Science ®Google Scholar
• Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y. and Ueno, K. (1996) "A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet", Biol. Phann. Bull. 19, 1518–1520.
   PubMed Web of Science ®Google Scholar